NanoSphere Closes $1.335M First Tranche of Private Placement
DENVER–(BUSINESS WIRE)–NanoSphere
Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) the biotechnology
leader behind the patented NanoSphere Delivery System™, is pleased to
announce a first tranche closing of its non-brokered private placement
announced November 28, 2018. Pursuant to the first tranche, the company
issued 4,452,254 Units at a price of $0.30 per Unit for gross proceeds
of CAD $1,335,676.
Each Unit was comprised of one common share and a full purchase warrant
exercisable to purchase a further common share at a price of $0.50 for a
period of 24 months, subject to accelerated expiry if the company’s
shares trade at or above $0.75 for 15 consecutive days. In connection
with the closing, the company paid an aggregate of $22,636 in finder
fees and issued 17,500 finder warrants having the same terms as the
private placement warrants. All securities issued are subject to a
statutory hold period expiring April 15, 2019.
About NanoSphere
NanoSphere Health Sciences LLC, is a biotechnology firm specializing in
the creation of the patented NanoSphere Delivery System™, a
revolutionary platform using nanotechnology in the biodelivery of
supplements, nutraceuticals and over-the-counter medications for the
cannabis, pharmaceutical and animal health industries, and beyond. For
more information, please visit http://www.nanospherehealth.com.
About Evolve Formulas
NanoSphere Health’s Evolve Formula’s line, currently consists of three
variations of the transdermal NanoSerum™ formula, one THC-dominant,
CBD-dominant and hemp-derived CBD. All applications utilize the
NanoSphere Delivery System™, for increased bioavailability, minimal
wait-time and precision-metered dosing. This patented technology is the
first and only advanced cannabinoid delivery system and can only be
found in NanoSphere Health products. For more information on Evolve
Formulas, visit https://www.evolveformulas.com/.
The Canadian Securities Exchange does not accept responsibility for
the adequacy or accuracy of this release.
Forward Looking Statement Caution
This news release includes forward looking statements that are
subject to assumptions, risks and uncertainties. Statements in this news
release which are not purely historical are forward looking statements,
including without limitation any statements concerning the Company’s
intentions, plans, estimates, expectations or beliefs regarding the
future. Although the Company believes that any forward looking
statements in this news release are reasonable, there can be no
assurance that any such forward looking statements will prove to be
accurate. The Company cautions readers that all forward looking
statements, including without limitation those relating to the Company’s
future operations and business prospects, are based on assumptions none
of which can be assured, and are subject to certain risks and
uncertainties that could cause actual events or results to differ
materially from those indicated in the forward looking statements.
Without limitation, these include assumptions, risks and uncertainties
inherent in completing sublicensing arrangements in the United States,
Canada and abroad, product demand, production, competition and
government regulation of the Cannabis industry, any and all of which may
have an adverse effect on the Company’s expansion plans, sales, revenues
and its financial results and condition. Readers are advised to
rely on their own evaluation of such risks and uncertainties and should
not place undue reliance on forward looking statements. Any forward
looking statements are made as of the date of this news release, and the
Company assumes no obligation to update the forward looking statements,
or to update the reasons why actual events or results could or do differ
from those projected in the forward looking statements, whether as a
result of new information, future events or otherwise.
Contacts
Gary Symons
gsymons@nanospherehealth.com
250-300-9352
On behalf of the Board
David Sutton, President and COO
720.520.4283
dsutton@nanospherehealth.com
Investor Contact:
Victor Goncalves, Executive Vice President
204.997.5517
vgoncalves@nanospherehealth.com
